

BAL PHARMA LIMITED
 Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
 Ph : 080 41379400, Fax: 080 22354057, email: secretarial@balpharma.com
 CIN # LS5110KA1987PLC008368
UNAUDITED STANDALONE FINANCIAL RESULTS FOR QUARTER ENDED 30.06.2017

Rs in Lakhs

Sl No.	Particulars	Quarter Ended	
		30.06.2017 Unaudited	30.06.2016 Unaudited
	Income		
1	Revenue from operations	4,542.88	4,467.15
2	Other income	78.19	77.36
3	Total Income - (i)	4,621.07	4,544.51
4	Expenses		
	a) Cost of materials consumed	2,283.55	2,052.65
	b) Purchase of Stock-in-trade	160.46	174.33
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-483.60	-120.31
	d) Employees benefits expenses	1,131.78	939.09
	f) Finance costs	184.83	193.57
	g) Depreciation and amortization expense	144.80	149.32
	h) Other expenses	1,099.73	1,071.13
	Total Expense - (IV)	4,521.54	4,459.78
5	Profit before Exceptional item and Tax (III-IV)	99.53	84.73
6	Exceptional items	-	-
7	Profit/ (Loss) before Tax (V-VI)	99.53	84.73
8	Tax Expense	28.41	20.94
9	Net Profit for the period	71.12	63.79
10	Other Comprehensive Income, net of Income Tax		
	- Items that may be reclassified to Profit or loss	-	-
	- Items that may not be reclassified to Profit or loss	-12.88	-4.63
	Total Other Comprehensive income, net of Income Tax	-12.88	-4.63
11	Total Comprehensive income (9+10)	58.24	59.16
12	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,417.24	1,417.24
13	Reserves	-	-
14	Earnings per share (Face value of ₹ 10 each)		
	Basic - in ₹	0.50	0.45
	Diluted - in ₹	0.50	0.45


Notes:


- The above results, as reviewed by the Audit committee, were considered and approved by the Board of Directors at its meeting held on 11th September 2017.
- Results of the quarter ended 30 June 2017 were subjected to 'limited review' by the Auditors and their report contains no qualifications.
- The results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and as per provisions prescribed under Section 133 of the Companies Act, 2013.
- These results do not include Ind AS compliant results for the immediate preceding quarter and previous year ended 31st March 2017 as the same is not mandatory as per SEBI circular dated 5th July 2016.
- Reconciliation of net profit for the corresponding previous quarter ended 30.06.2016 in accordance with the Indian GAAP to total comprehensive Income.

Particulars	Amount in ₹ Lakhs
Net Profit under previous GAAP	59.16
Ind AS Adjustments:	
Actuarial loss on employee defined benefit funds recognised in Other Comprehensive	6.17
Impact of current and deferred taxes	-1.54
Net Profit for the period under Ind AS	63.79

- As the Company deals with single product i.e., pharmaceuticals, segment wise figures are not furnished.
- Figures for the previous year/ period have been regrouped wherever necessary.

Place: Bengaluru
 Date: 11.09.2017

For Bal Pharma Limited

 Shallesh D Siroya
 Managing Director





T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356135, 22356137
Telefax : 080-22356136
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIALS RESULTS
FOR THE QUARTER ENDED JUNE 30, 2017

To
Board of Directors
Bal Pharma Limited


We have reviewed the accompanying statement of standalone unaudited financial results of BAL PHARMA LIMITED ("the company") for the quarter ended 30 June, 2017 ("the Statement"), prepared and being submitted by the Company pursuant to requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants
Firm registration no: 002491S


T D JAIN
Partner
M No: 012034

Place: Bangalore
Date: 11.09.2017



BAL PHARMA LIMITED
AUDITED FINANCIAL RESULTS (CONSOLIDATED) FOR THE QUARTER ENDED 30 JUNE, 2017.

		Rs in Lakhs	
Sl No.	Particulars	Quarter Ended	
		30.06.2017 Unaudited	30.06.2016 Unaudited
	Income		
1	Revenue from operations	4,598.39	4571.39
2	Other income	75.34	77.36
3	Total Income - (i)	4,673.73	4,648.75
4	Expenses		
	a) Cost of materials consumed	2,283.55	2052.65
	b) Purchase of Stock-in-trade	186.19	180.18
	c) Changes in inventories of finished goods, Stock-in-trade work-in-progress	-	-127.50
	d) Employees benefits expenses	1,214.73	1,023.79
	f) Finance costs	185.22	193.62
	g) Depreciation and amortization expense	145.64	150.05
	h) Other expenses	1,195.98	1,102.28
	Total Expense - (IV)	4,709.28	4,575.07
5	Profit before Exceptional item and Tax (III-IV)	-35.55	73.68
6	Exceptional items	-	-
7	Profit/ (Loss) before Tax (V-VI)	-35.55	73.68
8	Tax Expense	28.41	21.53
9	Net Profit for the period	-63.96	52.15
10	Other Comprehensive Income, net of Income Tax		
	- Items that may be reclassified to Profit or loss	-	-
	- Items that may not be reclassified to Profit or loss	-12.79	-5.22
	Total Other Comprehensive income, net of Income Tax	-12.79	-5.22
11	Total Comprehensive income (9+10)	-76.75	46.93
12	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,417.24	1,417.24
13	Reserves	-	-
14	Earnings per share (Face value of ₹ 10 each)		
	Basic - in ₹	-0.05	0.04
	Diluted - in ₹	-0.05	0.04



Notes:


1. The above results, as reviewed by the Audit committee, were considered and approved by the Board of Directors at its meeting held on 11 September 2017.
2. Results for the quarter ended 30 June 2017 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. The results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices to the extent applicable. Effective from 1 April 2017, the Company has, for the first time, adopted Ind AS with a transition date of 1 April 2016.
4. These results do not include Ind AS compliant results for the immediate preceding quarter and previous year ended 31 March 2017 as the same is not mandatory as per SEBI's circular dated 5th July, 2016.
5. Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter ended 30 June 2016

Particulars	Amount in ₹ Lakhs
Net Profit under previous GAAP	46.92
Ind AS Adjustments:	
Actuarial loss on employee defined benefit funds recognised in Otl	7.35
Impact of current and deferred taxes	-2.13
Net Profit for the period under Ind AS	<u>52.15</u>

6. As the Company deals with single product i.e., pharmaceuticals, segment wise figures are not furnished.
7. Figures for the previous year/ period have been regrouped wherever necessary.

Place: Bengaluru
Date: 11.09.2017

For Bal Pharma Limited



Shailesh D Siroya
Managing Director



T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356135, 22356137
Telefax : 080-22356136
E-mail : ostawa@jain@gmail.com

LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIALS RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

To
Board of Directors
Bal Pharma Limited

We have reviewed the unaudited consolidated financial results of BAL PHARMA LIMITED ("the company") and its subsidiaries (hereafter referred to as the "Group") for the quarter ended 30 June 2017 which are included in the accompanying Unaudited Consolidated Financial results for the quarter ended June 30 2017 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been installed by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

The statement includes the financial results of following entities:


Lifezen Healthcare Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results, prepared in accordance with the applicable Accounting Standards i.e. Ind AS Prescribed under section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants
Firm registration no: 002491S


T D JAIN
Partner
M No: 012034

Place: Bangalore
Date: 11.09.2017

